INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)	3 Months Ended			9 Months Ended	12 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Aug. 02, 2022
Finite-Lived Intangible Assets [Line Items]
Cost					$ 981,016,000	$ 1,042,808,000
Finite-lived intangible assets, accumulated amortization					274,776,000	198,397,000
Finite-lived Intangible assets, net					706,240,000	844,411,000
Goodwill, impairment loss					0	0	$ 0
Oncotype DX Genomic Prostate Score Test | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Finite-Lived Intangible Assets [Line Items]
Cost								$ 59,000,000
Finite-lived intangible assets, accumulated amortization								16,100,000
Finite-lived Intangible assets, net								$ 42,900,000
Supply agreement
Finite-Lived Intangible Assets [Line Items]
Cost						2,295,000
Finite-lived intangible assets, accumulated amortization						101,000
Finite-lived Intangible assets, net						2,194,000
Impairment of long-lived assets	$ 2,000,000
Developed technology
Finite-Lived Intangible Assets [Line Items]
Cost					861,474,000	918,171,000
Finite-lived intangible assets, accumulated amortization					245,527,000	176,402,000
Finite-lived Intangible assets, net					$ 615,948,000	$ 741,769,000
Impairment of long-lived assets		$ 6,600,000
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets			$ 20,200,000
In-process research and development | Armune Biosciences Agreement
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets							$ 9,700,000
In-process research and development | Biocartis Agreement
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets				$ 200,000,000